Core Viewpoint - Bank of America Securities has initiated coverage on MicroPort Medical (00853) with a "Buy" rating and a target price of HKD 16.8, citing the elimination of recent liquidity pressures and a shift in investor focus back to fundamentals [1] Group 1: Financial Performance and Projections - The company is expected to achieve profitability by the first half of 2026 through cost control and divestment of non-core assets [1] - Revenue projections for 2025, 2026, and 2027 are USD 1.109 billion, USD 1.241 billion, and USD 1.407 billion, representing year-on-year growth rates of 7.6%, 11.9%, and 13.3% respectively [1] Group 2: Strategic Developments - The introduction of Shanghai Industrial, a state-owned enterprise, as a strategic shareholder is anticipated to support the company's financial and business development [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1] Group 3: Cost Management - The company is projected to further reduce operating expense ratios and financing costs [1]